The proposed bonus for Olivier Brandicourt, the new chief executive of Sanofi (Euronext: SAN) has drawn criticism from government and trade unions.
Dr Brandicourt is set to receive a golden handshake of 4 million euros ($4.6 million), with 2 million euros upon taking up the post in April, and an additional 2 million in January 2016. The company said he would be paid a fixed salary of 1.2 million euros a year plus a performance-related amount targeted at 150% of his salary with a cap at 250%.
Reuters reported that Stéphane Le Foll, a government spokesperson, spoke out against Brandicourt “being assured of an incommensurate remuneration without even having taken the head of the company,” while Ségolène Royal, the minister for energy and the environment, called the bonus “not at all normal,” and appealed to “decency.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze